Kura Oncology (KURA) Competitors

Kura Oncology (NASDAQ:KURA) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.

Is KURA or CNTA more profitable?

Kura Oncology's return on equity of -44.09% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	N/A	-44.09%	-39.57%
Centessa Pharmaceuticals	N/A	-52.13%	-38.01%

Does the MarketBeat Community believe in KURA or CNTA?

Kura Oncology received 401 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 69.55% of users gave Kura Oncology an outperform vote while only 60.00% of users gave Centessa Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Kura Oncology	Outperform Votes 434 69.55%	Underperform Votes 190 30.45%
Centessa Pharmaceuticals	Outperform Votes 33 60.00%	Underperform Votes 22 40.00%

Do analysts recommend KURA or CNTA?

Kura Oncology currently has a consensus price target of $25.50, indicating a potential upside of 257.14%. Centessa Pharmaceuticals has a consensus price target of $26.00, indicating a potential upside of 79.19%. Given Kura Oncology's higher possible upside, research analysts plainly believe Kura Oncology is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92
Centessa Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger earnings & valuation, KURA or CNTA?

Centessa Pharmaceuticals has lower revenue, but higher earnings than Kura Oncology. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$53.88M	10.70	-$152.63M	-$2.03	-3.52
Centessa Pharmaceuticals	$6.85M	279.16	-$151.09M	-$1.99	-7.29

Does the media refer more to KURA or CNTA?

In the previous week, Centessa Pharmaceuticals had 6 more articles in the media than Kura Oncology. MarketBeat recorded 17 mentions for Centessa Pharmaceuticals and 11 mentions for Kura Oncology. Centessa Pharmaceuticals' average media sentiment score of 0.98 beat Kura Oncology's score of 0.66 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, KURA or CNTA?

Kura Oncology has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of KURA or CNTA?

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 5.5% of Kura Oncology shares are owned by insiders. Comparatively, 11.6% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Centessa Pharmaceuticals beats Kura Oncology on 10 of the 17 factors compared between the two stocks.